Pricing Log in Create free account

Aclaris Therapeutics, Inc. (ACRS) vs CytomX Therapeutics, Inc. (CTMX)

Aclaris Therapeutics, Inc. and CytomX Therapeutics, Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and CytomX Therapeutics, Inc. are of similar size ($525.1M and $513.7M). Aclaris Therapeutics, Inc. grew revenue faster over the last twelve months: −51.0% against −87.0%. CytomX Therapeutics, Inc. has the higher net margin (−451.6% vs −921.5%) and the higher return on invested capital (0.00% vs −163.4%). Across the 17 metrics below, CytomX Therapeutics, Inc. leads on 11 and Aclaris Therapeutics, Inc. on 6.

Valuation

Metric ACRS CTMX Biotechnology median
P/E n/m n/m 8.50
P/S 56.96 27.16 9.71
P/B 3.76 1.65 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 47.13 9.28 9.21
Earnings yield (17.68%) (22.03%) (33.15%)
Free cash flow yield (13.28%) (16.63%) (25.50%)

Profitability

Metric ACRS CTMX Biotechnology median
Gross margin 12.90% 100.00% 65.16%
Operating margin (1,050.16%) (476.19%) 0.00%
Net margin (921.50%) (451.62%) 0.00%
Free cash flow margin (756.50%) (450.27%) 0.00%
Return on equity (59.10%) (39.18%) (56.36%)
Return on assets (41.07%) (29.72%) (48.04%)
Return on invested capital (163.35%) 0.00% 0.00%

Growth

Metric ACRS CTMX Biotechnology median
Revenue growth (TTM) (51.04%) (87.03%) 6.02%
EPS growth (last fiscal year) 69.01% (139.47%) 30.26%
Revenue growth, 5-year CAGR 3.84% (5.36%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRS CTMX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.46 9.36 4.72
Net debt to EBITDA 1.20 5.91 0.96

Dividend

Metric ACRS CTMX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACRS CTMX Biotechnology median
Market cap 513.72m 525.14m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack